Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

Anca Chelariu-Raicu; Charles F Levenback; Brian M Slomovitz; Judith Wolf; Diane C Bodurka; John J Kavanagh; Christopher Morrison; David M Gershenson; Robert L Coleman

doi:10.1136/ijgc-2020-001863

Article info

Original research

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

Authors

Anca Chelariu-Raicu Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Charles F Levenback Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Brian M Slomovitz Division of Gynecologic Oncology, Broward Health Medical Center, Fort Lauderdale, Florida, USA PubMed articles Google scholar articles
Judith Wolf Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Diane C Bodurka Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
John J Kavanagh Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand PubMed articles Google scholar articles
Christopher Morrison Atrius Health, Boston, Massachusetts, USA PubMed articles Google scholar articles
David M Gershenson Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Robert L Coleman Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA The US Oncology Network, The Woodlands, Texas, USA PubMed articles Google scholar articles

Correspondence to Dr Robert L Coleman, The US Oncology Network, The Woodlands, TX 77380, USA; rcoleman{at}gog.org

View Full Text

Citation

Chelariu-Raicu A, Levenback CF, Slomovitz BM, et al

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

International Journal of Gynecologic Cancer 2020;30:1768-1774.

Publication history

Received July 16, 2020
Revision received August 17, 2020
Accepted August 25, 2020
First published October 9, 2020.

Online issue publication

January 08, 2022

Article Versions

Previous version (2 November 2020).
Previous version (2 November 2020).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password